person · Reporting owner
Balachandran Madhavan
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | EVP, Operations | May 03, 2016 | May 06, 2016 |
| Catalent, Inc.CTLT · Entity 16279 | Director | October 27, 2023 | October 31, 2023 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2026 | April 08, 2026 |
| Stevanato Group S.p.A.STVN · Entity 3826 | Director | June 12, 2026 | June 26, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 03, 2016 · Filed May 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 55,996 |
Reported balance
After 2016-05-04 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-05-04 · Sale · Disposed 30,000 · Balance 55,996 F1: The price reported is an average price. The prices ranged from $153.53 to $154.54 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. |
| Common StockSEC Table I · non-derivative | Direct | 23,097 |
Reported balance
After 2016-05-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2016-05-03 · Grant · Acquired 3,581 · Balance 23,097 F2: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F3: These shares include the following RSUs granted under the Company's equity plans: 9,056 RSUs which vest in one installment on 7/31/2016; 2,543 RSUs which vest on 1/28/2017; 3,154 RSUs which vest in one installment of 1,553 on 1/31/2017 and one installment of 1,601 on 1/31/2018; 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019; and 3,581 RSUs which vest in installments of 1,181 on 5/3/2018, 1,182 on 5/3/2019 and 1,218 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F4: These shares include 1,086 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.35 · Expires 2026-05-03 | Direct | 30,490 |
Reported balance
After 2016-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-05-03 · Grant · Acquired 30,490 · Balance 30,490 F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is an average price. The prices ranged from $153.53 to $154.54 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer.
F2: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
F3: These shares include the following RSUs granted under the Company's equity plans: 9,056 RSUs which vest in one installment on 7/31/2016; 2,543 RSUs which vest on 1/28/2017; 3,154 RSUs which vest in one installment of 1,553 on 1/31/2017 and one installment of 1,601 on 1/31/2018; 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019; and 3,581 RSUs which vest in installments of 1,181 on 5/3/2018, 1,182 on 5/3/2019 and 1,218 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F4: These shares include 1,086 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
Catalent, Inc.
Report date October 27, 2023 · Filed October 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,441 |
Reported balance
After 2023-10-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-27 · Grant · Acquired 6,993 · Balance 27,441 F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service. F2: Includes restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service.
F2: Includes restricted stock units.
Replimune Group, Inc.
Report date April 01, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2036-04-01 | Direct | 44,500 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 44,500 · Balance 44,500 F1: The shares underlying this option vest entirely on April 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest entirely on April 1, 2027.
Stevanato Group S.p.A.
Report date June 12, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 69,458 |
Ending reported balance
After 2026-06-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Grant · Acquired 4,975 · Balance 70,951 F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director. Row 2 · 2026-06-15 · Sale · Disposed 1,493 · Balance 69,458 F2: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director.
F2: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares.
uniQure N.V.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 43,254 |
Ending reported balance
After 2026-06-17 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-06-17 · Exercise / conversion · Acquired 5,295 · Balance 48,549 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Row 2 · 2026-06-17 · Exercise / conversion · Acquired 6,390 · Balance 54,939 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Row 3 · 2026-06-17 · Sale · Disposed 5,295 · Balance 49,644 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.00 to $47.36. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 4 · 2026-06-17 · Sale · Disposed 4,700 · Balance 44,944 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.12 to $43.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. Row 5 · 2026-06-17 · Sale · Disposed 1,690 · Balance 43,254 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $42.93. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.71 · Expires 2029-01-25 | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-17 · Exercise / conversion · Disposed 5,295 · Balance 0 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5: The Stock Option vested in full on January 25, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.39 · Expires 2028-01-26 | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-06-17 · Exercise / conversion · Disposed 6,390 · Balance 0 F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F6: The Stock Option vested in full on January 26, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on March 10, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.00 to $47.36. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.12 to $43.95. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.50 to $42.93. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
F5: The Stock Option vested in full on January 25, 2020.
F6: The Stock Option vested in full on January 26, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2014 Filed Apr 29, 2014 21:35 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 740 | $113.72 | $84,152.80 |
DisclosureSEC source: 0001127602-14-015503 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,623 Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 20:18 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 5,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-012000 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 40,131 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 20:18 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 5,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-012000 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,363 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,143 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 20:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 5,763 | $123.96 | $714,381.48 |
DisclosureSEC source: 0001127602-14-012000 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,623 Read SEC document |
| March 05, 2014 Filed Mar 7, 2014 22:25 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 11,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-010748 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,195 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 932 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:37 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-004375 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,152 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 932 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| September 04, 2013 Filed Sep 5, 2013 23:33 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $58.43 | $0.00 |
DisclosureSEC source: 0001127602-13-026729 · form4.xml · derivative · entry 5 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 18,000 shares Expires 2020-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2013 Filed Sep 5, 2013 23:33 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 18,000 | $112.76 | $2,029,768.20 |
DisclosureSEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 4 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 34,851 F4 · price: The price reported is an average price. The prices ranged from $112.66 to $112.90 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. Read SEC document |
| September 04, 2013 Filed Sep 5, 2013 23:33 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,133 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 620 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| September 04, 2013 Filed Sep 5, 2013 23:33 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 52,851 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| September 04, 2013 Filed Sep 5, 2013 23:33 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 18,000 | $58.43 | $1,051,740.00 |
DisclosureSEC source: 0001127602-13-026729 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2013 Filed May 22, 2013 00:18 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-13-017759 · form4.xml · derivative · entry 5 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2016-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2013 Filed May 22, 2013 00:18 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 6,000 | $103.28 | $619,681.20 |
DisclosureSEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 4 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 34,851 F4 · price: The price reported is an average price. The prices ranged from $103.18 to $103.42 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. Read SEC document |
| May 21, 2013 Filed May 22, 2013 00:18 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,956 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 21, 2013 Filed May 22, 2013 00:18 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 40,851 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| May 21, 2013 Filed May 22, 2013 00:18 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 6,000 | $50.44 | $302,640.00 |
DisclosureSEC source: 0001127602-13-017759 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2013 Filed Apr 30, 2013 21:08 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 426 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 6 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,956 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 875 RSUs which fully vest on 4/26/2014; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 28, 2013 Filed Apr 30, 2013 21:08 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 426 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 5 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 34,851 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| April 28, 2013 Filed Apr 30, 2013 21:08 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 424 | $108.38 | $45,953.12 |
DisclosureSEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 4 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,382 Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:08 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 438 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,806 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:08 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 438 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 34,425 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:08 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 437 | $108.66 | $47,484.42 |
DisclosureSEC source: 0001127602-13-014765 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,244 Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 21:54 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014701 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,681 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 850 RSUs which fully vest on 4/28/2013; 1,750 RSUs which vest in two equal annual installments of 875 each commencing 4/26/2013; 3,015 RSUs which vest in one installment of 1,485 on 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 21:54 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014701 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 33,987 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 21:54 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 740 | $104.93 | $77,648.20 |
DisclosureSEC source: 0001127602-13-014701 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,426 Read SEC document |
| March 15, 2013 Filed Mar 19, 2013 23:37 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 4,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-011468 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,166 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 850 RSUs which fully vest on 4/28/2013; 1,750 RSUs which vest in two equal annual installments of 875 each commencing 4/26/2013; 4,500 RSUs which vest in two equal installments of 1,485 each on 4/25/2013 and 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 443 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 15, 2013 Filed Mar 19, 2013 23:37 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 4,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-011468 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 33,242 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| March 15, 2013 Filed Mar 19, 2013 23:37 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 5,188 | $92.18 | $478,229.84 |
DisclosureSEC source: 0001127602-13-011468 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,920 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 23:18 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 9,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-010158 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,922 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 850 RSUs which fully vest on 4/28/2013; 1,750 RSUs which vest in two equal annual installments of 875 each commencing 4/26/2013; 4,500 RSUs which vest in two equal installments of 1,485 each on 4/25/2013 and 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 257 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2013 Filed Jan 31, 2013 01:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 7,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-003257 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,980 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 850 RSUs which fully vest on 4/28/2013; 1,750 RSUs which vest in two equal annual installments of 875 each commencing 4/26/2013; 4,500 RSUs which vest in two equal installments of 1,485 each on 4/25/2013 and 4/25/2014 and one installment of 1,530 on 4/25/2015; 2,512 RSUs which vest in three installments of 828, 829 and 855 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 26,634 RSUs which vest in two equal installments of 8,789 each on 7/31/2014 and 7/31/2015 and one installment of 9,056 on 7/31/2016; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 257 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.